Tillman Gerngross, Adagio CEO
Q&A: Tillman Gerngross explains why his Covid mAb will have an edge over an already crowded field
If anyone knows about monoclonal antibodies, it’s serial entrepreneur, Adimab CEO, and Dartmouth professor of bioengineering Tillman Gerngross.
Even the name of Gerngross’ new antibody …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
